Profile data is unavailable for this security.
About the company
Nxera Pharma Co Ltd, formerly known as Sosei Group Corp, is a Japan-based company engaged in the biopharmaceutical business that handles from drug research (drug discovery) to development and sale. The Company is mainly engaged in the pharmaceutical business. The Company is engaged in drug discovery, translational medicine, preclinical and early clinical development, as well as the research and development, import/export, packaging, and sale of pharmaceuticals. The Company also conducts structural analysis of G protein-coupled receptors (GPCRs), creates initial lead compounds, and searches for candidate products using StaR technology.
- Revenue in JPY (TTM)16.43bn
- Net income in JPY-9.07bn
- Incorporated1990
- Employees350.00
- LocationNxera Pharma Co LtdMidtown East, 9-7-2, AkasakaMINATO-KU 107-0052JapanJPN
- Phone+81 352103290
- Fax+81 352103291
- Websitehttps://www.nxera.life/
More ▼
Mergers & acquisitions
| Acquired company | 4565:TYO since announced | Transaction value |
|---|---|---|
| Idorsia Pharmaceuticals Korea Co Ltd | 12.88% | 135.00k |
| Idorsia Pharmaceuticals Japan Ltd | 12.88% | 51.72m |
| Idorsia Ltd-Ex-China APAC/Japan Pharmaceuticals business | 12.88% | 465.98m |
Data delayed at least 20 minutes, as of Jul 17 2024 05:59 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| JCR Pharmaceuticals Co Ltd | 42.87bn | 5.51bn | 82.35bn | 934.00 | 14.46 | 1.41 | 9.43 | 1.92 | 43.92 | 43.92 | 342.31 | 450.13 | 0.4349 | 0.5891 | 3.29 | 45,900,430.00 | 5.62 | 8.66 | 8.47 | 13.46 | 72.90 | 74.51 | 12.92 | 18.24 | 1.22 | 27.69 | 0.2932 | 30.60 | 24.83 | 13.11 | 46.00 | 8.19 | 18.54 | 21.67 |
| Torii Pharmaceutical Co Ltd | 56.28bn | 5.29bn | 109.87bn | 583.00 | 20.29 | 0.9007 | 19.13 | 1.95 | 188.05 | 188.05 | 2,002.44 | 4,235.56 | 0.4288 | 2.72 | 2.25 | 96,531,740.00 | 4.03 | 6.52 | 4.44 | 7.35 | 44.83 | 49.55 | 9.40 | 17.98 | 5.58 | -- | 0.00 | 24.17 | 11.74 | -2.67 | 4.44 | 28.76 | -20.38 | 20.11 |
| Kyorin Pharmaceutical Co Ltd | 119.53bn | 5.32bn | 111.00bn | 2.04k | 18.64 | 0.7591 | 11.55 | 0.9286 | 92.70 | 92.70 | 2,082.82 | 2,276.51 | 0.6759 | 1.34 | 2.61 | 58,536,730.00 | 3.01 | 3.05 | 3.90 | 3.79 | 43.01 | 47.11 | 4.45 | 4.76 | 1.45 | -- | 0.1389 | 67.74 | 5.53 | 1.02 | 12.68 | -4.98 | 7.41 | -7.06 |
| Zeria Pharmaceutical Co Ltd | 75.73bn | 7.73bn | 114.21bn | 1.78k | 12.26 | 1.19 | 7.49 | 1.51 | 175.39 | 175.39 | 1,717.90 | 1,806.33 | 0.5304 | 1.48 | 3.99 | 42,614,000.00 | 5.39 | 3.89 | 8.39 | 6.28 | 73.29 | 71.93 | 10.16 | 7.57 | 0.7946 | 11.75 | 0.3735 | 35.09 | 10.74 | 4.14 | 24.78 | 17.49 | 20.77 | 5.29 |
| Mochida Pharmaceutical Co Ltd | 102.89bn | 4.55bn | 126.27bn | 1.52k | 26.68 | 0.9336 | 17.17 | 1.23 | 126.33 | 126.33 | 2,868.83 | 3,609.59 | 0.6478 | 1.86 | 3.28 | 67,598,550.00 | 2.86 | 4.37 | 3.44 | 5.31 | 50.61 | 52.47 | 4.42 | 6.71 | 3.31 | -- | 0.0029 | 45.16 | -0.3641 | -1.26 | -31.61 | -11.63 | 10.91 | -1.21 |
| Nxera Pharma Co Ltd | 16.43bn | -9.07bn | 151.04bn | 350.00 | -- | 2.28 | -- | 9.19 | -107.30 | -107.30 | 194.96 | 736.60 | 0.1309 | -- | 5.77 | 46,954,280.00 | -7.23 | -0.6588 | -7.78 | -0.7036 | 74.44 | 89.83 | -55.20 | -4.46 | 4.03 | -10.91 | 0.5238 | -- | -18.00 | -- | -1,982.98 | -- | -- | -- |
| Towa Pharmaceutical Co Ltd | 227.93bn | 16.17bn | 157.38bn | 4.59k | 9.30 | 0.9646 | 4.62 | 0.6905 | 328.58 | 328.58 | 4,630.88 | 3,167.26 | 0.5684 | 1.51 | 3.70 | 49,680,470.00 | 4.03 | 4.21 | 5.03 | 5.63 | 35.70 | 39.23 | 7.10 | 7.23 | 1.46 | -- | 0.5649 | 21.01 | 9.13 | 16.74 | 634.80 | 3.72 | 28.20 | 10.86 |
| Kissei Pharmaceutical Co Ltd | 75.58bn | 11.16bn | 160.51bn | 1.78k | 13.20 | 0.654 | 10.33 | 2.12 | 246.57 | 246.57 | 1,669.95 | 4,977.43 | 0.3135 | 1.56 | 2.94 | 42,483,980.00 | 4.68 | 3.61 | 5.05 | 3.90 | 49.41 | 49.47 | 14.94 | 12.69 | 4.43 | -- | 0.0078 | 34.87 | 11.98 | 0.8919 | 6.00 | 15.28 | 6.58 | 10.40 |
| Sumitomo Pharma Co Ltd | 314.56bn | -314.97bn | 163.93bn | 4.98k | -- | 1.05 | -- | 0.5212 | -792.79 | -792.79 | 791.76 | 392.82 | 0.308 | 1.21 | 4.05 | 63,164,260.00 | -30.84 | -5.07 | -54.58 | -7.73 | 59.76 | 69.99 | -100.12 | -12.28 | 0.2992 | -- | 0.7332 | -- | -43.38 | -7.29 | -322.71 | -- | 4.02 | -- |
| KAKEN PHARMACEUTICAL CO., LTD. | 72.04bn | 8.03bn | 186.42bn | 1.14k | 19.07 | 1.07 | 17.30 | 2.59 | 212.76 | 212.76 | 1,909.11 | 3,796.04 | 0.4264 | 2.05 | 3.40 | 63,474,890.00 | 4.75 | 6.83 | 5.40 | 7.87 | 53.49 | 54.78 | 11.14 | 14.48 | 4.72 | -- | 0.0261 | 51.25 | -1.29 | -5.21 | 47.52 | -14.70 | 0.3639 | 0.00 |
Data as of Jul 17 2024. Currency figures normalised to Nxera Pharma Co Ltd's reporting currency: Japanese Yen JPY
26.57%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Taiyo Pacific Partners LPas of 11 Jan 2024 | 6.37m | 7.08% |
| Nomura Asset Management Co., Ltd.as of 14 Jun 2024 | 3.59m | 3.99% |
| The Vanguard Group, Inc.as of 04 Jul 2024 | 2.94m | 3.28% |
| Asset Management One Co., Ltd.as of 31 May 2024 | 2.34m | 2.60% |
| Capital Research & Management Co. (World Investors)as of 15 Feb 2024 | 1.84m | 2.05% |
| Mitsubishi UFJ Asset Management Co., Ltd.as of 05 Jul 2024 | 1.62m | 1.80% |
| Capital International KKas of 15 Feb 2024 | 1.35m | 1.50% |
| Nikko Asset Management Co., Ltd.as of 05 Jul 2024 | 1.31m | 1.46% |
| JPMorgan Asset Management (Japan) Ltd.as of 15 Jun 2023 | 1.30m | 1.45% |
| Daiwa Asset Management Co. Ltd.as of 31 May 2024 | 1.22m | 1.36% |
More ▼
Data from 31 Mar 2024 - 22 May 2024Source: FactSet Research Systems Inc.
